argenx SE
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
Description
argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2017-11-13 08:39 |
argenx to Present at Upcoming Investor Conferences
|
English | 102.3 KB | ||
| 2017-11-07 13:23 |
argenx announces results of extraordinary shareholders' meeting 2017
|
English | 102.9 KB | ||
| 2017-11-02 07:35 |
argenx to host KOL breakfast symposium on pemphigus vulgaris on November 10, 20…
|
English | 16.0 KB | ||
| 2017-10-30 09:03 |
argenx launches Phase I trial with subcutaneous formulation of ARGX-113
|
English | 91.1 KB | ||
| 2017-09-26 08:07 |
argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the tr…
|
English | 104.2 KB | ||
| 2017-09-25 13:02 |
argenx announces orphan drug designation for ARGX-113 for the treatment of myas…
|
English | 90.4 KB | ||
| 2017-09-22 07:23 |
Invitation to the extraordinary shareholders' meeting
|
English | 89.5 KB | ||
| 2017-09-20 07:23 |
argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune t…
|
English | 28.9 KB | ||
| 2017-09-05 14:13 | English | 804.7 KB | |||
| 2017-08-24 07:07 |
argenx reports second quarter business update and half-year 2017 financial resu…
|
English | 247.5 KB | ||
| 2017-08-17 07:30 |
argenx to host conference call & webcast to report second quarter business upda…
|
English | 90.1 KB | ||
| 2017-06-20 12:40 |
argenx receives second preclinical milestone payment in collaboration with LEO …
|
English | 150.7 KB | ||
| 2017-06-14 08:24 |
argenx presents update on Phase I data from ARGX-110 expansion study in patient…
|
English | 18.5 KB | ||
| 2017-06-13 07:30 |
argenx to Present at JMP Securities Life Sciences Conference
|
English | 19.1 KB | ||
| 2017-05-24 08:56 |
argenx announces closing of NASDAQ IPO
|
English | 92.0 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
